986 related articles for article (PubMed ID: 17689146)
1. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
Kavirajan H; Schneider LS
Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Battle CE; Abdul-Rahim AH; Shenkin SD; Hewitt J; Quinn TJ
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013306. PubMed ID: 33704781
[TBL] [Abstract][Full Text] [Related]
3. Cholinesterase inhibitors for Alzheimer's disease.
Birks J
Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
[TBL] [Abstract][Full Text] [Related]
5. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.
Raina P; Santaguida P; Ismaila A; Patterson C; Cowan D; Levine M; Booker L; Oremus M
Ann Intern Med; 2008 Mar; 148(5):379-97. PubMed ID: 18316756
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
[TBL] [Abstract][Full Text] [Related]
8. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
[TBL] [Abstract][Full Text] [Related]
9. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Rolinski M; Fox C; Maidment I; McShane R
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
[TBL] [Abstract][Full Text] [Related]
11. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
Kaduszkiewicz H; Zimmermann T; Beck-Bornholdt HP; van den Bussche H
BMJ; 2005 Aug; 331(7512):321-7. PubMed ID: 16081444
[TBL] [Abstract][Full Text] [Related]
12. Rivastigmine for vascular cognitive impairment.
Birks J; McGuinness B; Craig D
Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
[TBL] [Abstract][Full Text] [Related]
13. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
[TBL] [Abstract][Full Text] [Related]
14. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review.
Repantis D; Laisney O; Heuser I
Pharmacol Res; 2010 Jun; 61(6):473-81. PubMed ID: 20193764
[TBL] [Abstract][Full Text] [Related]
15. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Rodda J; Morgan S; Walker Z
Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
[TBL] [Abstract][Full Text] [Related]
16. Summaries for patients. Drug treatment for patients with dementia: American College of Physicians and American Academy of Family Physicians recommendations.
Ann Intern Med; 2008 Mar; 148(5):I41. PubMed ID: 18316749
[No Abstract] [Full Text] [Related]
17. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
[TBL] [Abstract][Full Text] [Related]
18. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
[TBL] [Abstract][Full Text] [Related]
19. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
20. Memantine for dementia.
Areosa SA; Sherriff F
Cochrane Database Syst Rev; 2003; (1):CD003154. PubMed ID: 12535459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
